Novartis Pharmaceuticals

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

This study looks back at the experiences of 35 adults with a rare kidney disease called C3G who received the drug iptacopan through a special early access program in Spain. Researchers will collect information on patient health, lab results, and how the disease responds to treatm…

This phase 3 trial tests the drug atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The study measures whether atrasentan reduces protein in the urine, a sign of kidney damage, over 36 weeks. All participants receive th…

This phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. …

This phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …

This study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well out…

This early-stage study tests a new drug called HJB647 in Japanese adults with elevated blood pressure or mild-to-moderate hypertension. The main goal is to check safety and how the drug moves through the body. About 74 participants will receive either HJB647 or a placebo, with do…

This early-stage study tests whether a new version of the cholesterol-lowering drug inclisiran, which includes an ingredient called polysorbate 80, is as safe and works as well as the current version. About 120 healthy adults with moderately high LDL cholesterol will receive a si…

This study tests a drug called pelacarsen in people who recently had a heart attack and have high levels of Lp(a), a type of fat in the blood that raises heart risk. The goal is to see if the drug can safely lower Lp(a) levels and improve heart health. About 240 adults in the US …

This study will follow 36 people with spinal muscular atrophy (SMA) who receive a gene therapy called onasemnogene abeparvovec (ITVISMA) injected into the spinal fluid. The goal is to see how well it works and how safe it is in everyday medical practice. Participants must be at l…

This study will look at how well a drug called ARNi (sacubitril/valsartan) lowers blood pressure in 500 adults with hypertension in the United Arab Emirates. Researchers will compare it to standard treatments like ACE inhibitors and calcium channel blockers. The goal is to see if…

This study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…

This study tests a new once-daily inhaler called QVM149, which combines three medicines (indacaterol, glycopyrronium, and mometasone furoate) to control asthma. It will enroll 304 teenagers aged 12 to 17 and compare the new inhaler to a standard twice-daily treatment (salmeterol/…

This phase 3 study tests whether ianalumab, given as a monthly injection, can reduce dry mouth and other symptoms in people with Sjögren's disease who have a high symptom burden. About 570 adults will receive either the drug or a placebo for 52 weeks. The main goal is to see if t…

This study looks at how men with advanced prostate cancer that no longer responds to hormone therapy are treated in real-world clinics across the United States. Researchers will analyze data from over 17,000 patients to see which therapies are used, in what order, and how long th…

This study looks at real-world data from over 1,000 men with metastatic castration-resistant prostate cancer (mCRPC) who have already received several standard treatments, including hormone therapy, chemotherapy, and a targeted radiation drug called Lu-177 PSMA-617. Researchers w…

This study looks at how eltrombopag is actually used and how well it works in patients with immune thrombocytopenia (ITP) who have already tried steroids. Researchers will collect data from healthcare providers in the US, UK, and Germany, focusing on platelet count improvements w…

This study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe…

This study follows 34 adults with moderate-to-severe hidradenitis suppurativa (HS) who are taking secukinumab as part of their routine care. Researchers will use a special CT scan to check if the drug affects the buildup of plaque in the heart arteries over 12 months. The goal is…

This study will review medical records of 400 adults in Kuwait with chronic myeloid leukemia (CML) who have received at least one type of targeted therapy (TKI). Researchers want to understand patient backgrounds, other health conditions, and how treatments are used in everyday p…

This study will look at how consistently nearly 6,000 adults in Italy take three newer cholesterol-lowering drugs (inclisiran, evolocumab, and alirocumab) over the long term. Researchers will analyze prescription records to measure adherence and persistence in everyday medical pr…

This study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treat…

This study will observe how the drug lutetium-177 vipivotide tetraxetan is actually used in patients with metastatic prostate cancer. Researchers will collect data from medical records across multiple countries, using AI to analyze treatment patterns and outcomes. The goal is to …

This study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…

This study follows 100 children aged 6 to 17 with juvenile psoriatic or enthesitis-related arthritis who are taking secukinumab. Researchers will observe how doctors adjust treatment after the disease becomes inactive, and whether patients experience flares. The goal is to learn …